| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
MIND4-19 targets SIRT2, a member of the sirtuin family of NAD⁺-dependent deacetylases. SIRT2 is primarily localized in the cytoplasm and deacetylates various substrates involved in cell cycle regulation, metabolism, and neuroprotection. By inhibiting SIRT2 with an IC50 of 7.0 μM, MIND4-19 modulates the acetylation status of its substrates. This inhibition has been associated with antitumor activity and potential therapeutic effects in Huntington's disease.
|
|---|---|
| ln Vitro |
In vitro, MIND4-19 is a potent SIRT2 inhibitor with an IC50 value of 7.0 μM. It exhibits antitumor activity. The compound is used as a research tool for studying the role of SIRT2 in various cellular processes, including cancer and neurodegenerative diseases.
|
| ln Vivo |
Specific in vivo data for MIND4-19 are limited in publicly available sources. Based on its in vitro mechanism, the compound has potential for studying Huntington's disease and cancer. However, detailed in vivo efficacy studies in animal models have not been extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro enzyme assays for MIND4-19 measure its inhibition of SIRT2 deacetylase activity. SIRT2 is incubated with varying concentrations of the compound, a peptide substrate containing an acetylated lysine residue, and NAD⁺. Deacetylation is measured by detecting the released product using fluorometric or mass spectrometric methods. The IC50 value of 7.0 μM is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for MIND4-19 are conducted in cancer cell lines or neuronal cell models relevant to Huntington's disease. Cells are treated with the compound at various concentrations, and SIRT2 activity is assessed by measuring the acetylation status of SIRT2 substrates. Cell viability, apoptosis, and other relevant endpoints are also assessed.
|
| Animal Protocol |
In vivo animal experiments with MIND4-19 have not been extensively documented. Typical study designs would involve administration of the compound in mouse models of Huntington's disease or cancer xenograft models. Dosing regimens and routes of administration would need to be optimized. The compound is for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MIND4-19 are not extensively characterized. The compound has a molecular formula of C22H19N3OS and a molecular weight of 373.47. Storage: powder at -20°C for 3 years; in solvent at -80°C for 1 year. Specific data on absorption, distribution, metabolism, and excretion are not available.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for MIND4-19 are limited. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
MIND4-19 has CAS number 129544-85-0, molecular formula C22H19N3OS, and molecular weight 373.47. It is a potent SIRT2 inhibitor with an IC50 of 7.0 μM. It exhibits antitumor activity and can be used for Huntington's disease research. Purity: ≥98%. Not for human use; for research purposes only.
|
| Molecular Formula |
C22H19N3OS
|
|---|---|
| Molecular Weight |
373.47
|
| Exact Mass |
373.124
|
| CAS # |
129544-85-0
|
| PubChem CID |
1162727
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1=C(SCC2C=CC=CC=2)N(C2C=CC=CC=2)C(COC2C=CC=CC=2)=N1
|
| InChi Key |
SSZGXGUFAAHHAF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H19N3OS/c1-4-10-18(11-5-1)17-27-22-24-23-21(16-26-20-14-8-3-9-15-20)25(22)19-12-6-2-7-13-19/h1-15H,16-17H2
|
| Chemical Name |
3-benzylsulfanyl-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~267.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6776 mL | 13.3880 mL | 26.7759 mL | |
| 5 mM | 0.5355 mL | 2.6776 mL | 5.3552 mL | |
| 10 mM | 0.2678 mL | 1.3388 mL | 2.6776 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
